Omnicell (OMCL) investor relations material

Executive summary

• Q2 2026 revenues reached $312M, up 7% year-over-year, driven by strong demand for connected devices, SaaS, and technical services, and supported by robust customer engagement and pipeline growth for Titan XT and OmniSphere platforms.

• Net income for Q2 2026 was $24.3M, up from $5.6M in Q2 2025, reflecting improved gross margins and a one-time $14M–$15M tariff refund.

• Organizational update: Nnamdi Njoku appointed President and COO to accelerate execution and operational focus.

• Recognized as a leader in medication management with a 30-year track record and a strong installed base among top U.S. health systems.

• Focused on delivering autonomous medication management solutions and investing in next-generation automation to improve efficiency and patient safety.

Financial highlights

• Q2 2026 total revenue: $312M; product revenue: $175M; service revenue: $137M; recurring revenue accounted for 52% of total, with SaaS and Expert Services at 22%.

• Non-GAAP EBITDA: $67M (includes $14M–$15M one-time tariff refund); non-GAAP gross margin: 50%–50.2%.

• GAAP EPS: $0.52; non-GAAP EPS: $0.94, both up sharply year-over-year.

• Free cash flow: $55.8M–$56M; cash and equivalents: $292M at June 30, 2026.

• Q2 2026 non-GAAP EBITDA margin: 21.5%; non-GAAP operating margin: 17.0%.

Outlook and guidance

• Full-year 2026 revenue guidance: $1.225B–$1.245B; non-GAAP EBITDA: $175M–$185M; non-GAAP EPS: $2.15–$2.30.

• Q3 2026 revenue guidance: $301M–$307M; non-GAAP EBITDA: $32M–$37M; non-GAAP EPS: $0.35–$0.43.

• Product bookings guidance revised to $425M–$560M, reflecting timing uncertainty, not demand deterioration.

• Year-end 2026 ARR guidance: $660M–$680M, revised due to slower consumables growth.

• Emphasis on platform adoption, market share gains, and upgrade cycles to support growth.